A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance

Differentiation

Volumn 70, Issue 9-10, 2002, Pages 599-609

  Yu, Joanne L ^a   Coomber, Brenda L ^b   Kerbel, R S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

Author keywords

Antiangiogenic therapy; Genetic instability; Hypoxia; Vascular dependence

Indexed keywords

IMATINIB; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; CANCER CELL; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CONTROLLED STUDY; GASTROINTESTINAL TUMOR; HUMAN; HUMAN CELL; MELANOMA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 12244289602     PISSN: 03014681     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-0436.2002.700913.x     Document Type: Review

References (40)

1. Aotake, T., Lu, C.D., Chiba, Y., Muraoka, R. and Tanigawa, N. (1999) Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res 5:135-142.
2. Apperley, J.F., Gardembas, M., Melo, J.V., Russell-Jones, R., Bain, B.J., Baxter, E.J., Chase, A., Chessells, J.M., Colombat, M., Dearden, C.E., Dimitrijevic, S., Mahon, F.X., Marin, D., Nikolova, Z., Olavarria, E., Silberman, S., Schultheis, B., Cross, N.C. and Goldman, J.M. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487.
3. Bedi, A., Pasricha, P.J., Akhtar, A.J., Barber, J.P., Bedi, G.C., Giardiello, F.M., Zehnbauer, B.A., Hamilton, S.R. and Jones, R.J. (1995) Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55:1811-1816.
4. Blagosklonny, M.V. (2001) Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol 19:257-262.
5. Bouck, N., Stellmach, V. and Hsu, S.C. (1996) How tumors become angiogenic. Adv Cancer Res 69:135-174.
6. Brown, J.M. (1998) Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine. Br J Cancer 77(Suppl 4):12-14.
7. Brown, J.M. (2000) Hypoxic cytotoxic agents: a new approach to cancer chemotherapy. Drug Resist Updat 3:7-13.
8. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P., Sedivy, J.M., Kinzler, K.W. and Vogelstein, B. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
9. Capdeville, R., Buchdunger, E., Zimmermann, J. and Matter, A. (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502.
10. Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C.J., Ratcliffe, P., Moons, L., Jain, R.K., Collen, D., Keshert, E. and Keshet, E. (1998) Role of HIF-lalpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490.
11. Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek, M., Fletcher, J.A., Silverman, S.G., Silberman, S.L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B.J., Corless, C., Fletcher, C.D. and Joensuu, H. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480.
12. Druker, B.J. (2002a) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1:31-36.
13. Druker, B.J. (2002b) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8:S14-S18.
14. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. and Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
15. Fearon, E.R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767.
16. Goldman, J.M. and Druker, B.J. (2001) Chronic myeloid leukemia: current treatment options. Blood 98:2039-2042.
17. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. and Sawyers, C.L. (2001) Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880.
18. Gorre, M.E. and Sawyers, C.L. (2002) Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 9:303-307.
19. Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W. and Giaccia, A.J. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91.
20. Graeber, T.G., Peterson, J.F., Tsai, M., Monica, K., Fornace, A.J.J. and Giaccia, A.J. (1994) Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14:6264-6277.
21. Heinrich, M.C., Blanke, C.D., Druker, B.J. and Corless, C.L. (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703.
22. Hlatky, L., Hahnfeldt, P. and Folkman, J. (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 19:883-893.
23. Hockel, M. and Vaupel, P. (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276.
24. Jain, R.K. (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Canc Inst 81:570-576.
25. Jain, R.K. (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989.
26. Kerbel, R.S. and Folkman, J. (2002) Anti-cancer therapy with angiogenesis inhibitors: experimental basis of translation from laboratory to clinic. Nat Rev Cancer (in press).
27. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D., Bohlen, P. and Kerbel, R.S. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24.
28. Klement, G., Mayer, B., Huang, P., Man, S., Bohlen, P., Hicklin, D. and Kerbel, R.S. (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenograft. Clin Cancer Res 8:221-232.
29. Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y., Lowe, S.W., Kastan, M. and Giaccia, A. (2001) Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21:1297-1310.
30. Lord, E.M., Harwell, L. and Koch, C.J. (1993) Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 53:5721-5726.
31. McCormick, F. (2001) New-age drug meets resistance. Nature 19:281-282.
32. Pirollo, K.F., Bouker, K.B. and Chang, E.H. (2000) Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11:419-432.
33. Pluquet, O. and Hainaut, P. (2001) Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett 174:1-15.
34. Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W. and Vogelstein, B. (1997) A model for p53-induced apoptosis. Nature 389:300-305.
35. Sausville, E.A. (2001) The challenge of pathway and environment-mediated drug resistance. Cancer Metastasis Rev 20:117-122.
36. Teicher, B.A., Holden, S.A., Ara, G., Dupuis, N.P., Liu, F., Yuan, J., Ikebe, M. and Kakeji, Y. (1995) Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 61:732-737.
37. Waldman, T., Kinzler, K.W. and Vogelstein, B. (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55:5187-5190.
38. Weidner, N., Semple, J.P., Welch, W.R. and Folkman, J. (1991) Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324:1-8.
39. Yu, J., Rak, J., Coomber, B.L., Hicklin, D. and Kerbel, R.S. (2002) Effect of p53 status on tumor response to anti-angiogenic therapy. Science 295:1526-1528.
40. Yu, J.L., Rak, J., Carmeliet, P., Nagy, A., Kerbel, R.S. and Coomber, B.L. (2001) Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 158:1325-1334.